ID   ODPA_HUMAN              Reviewed;         390 AA.
AC   P08559; A5YVE9; B2R5P7; B7Z3T7; B7Z3X5; Q53H41; Q5JPT8; Q9NP12;
AC   Q9UBJ8; Q9UBU0; Q9UNG4; Q9UNG5;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 3.
DT   10-MAY-2017, entry version 211.
DE   RecName: Full=Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial;
DE            EC=1.2.4.1;
DE   AltName: Full=PDHE1-A type I;
DE   Flags: Precursor;
GN   Name=PDHA1; Synonyms=PHE1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Leukocyte;
RX   PubMed=2227443; DOI=10.1016/0378-1119(90)90241-I;
RA   Koike K., Urata Y., Matsuo S., Koike M.;
RT   "Characterization and nucleotide sequence of the gene encoding the
RT   human pyruvate dehydrogenase alpha-subunit.";
RL   Gene 93:307-311(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2748588; DOI=10.1073/pnas.86.14.5330;
RA   Ho L., Wexler I.D., Liu T.C., Thekkumkara T.J., Patel M.S.;
RT   "Characterization of cDNAs encoding human pyruvate dehydrogenase alpha
RT   subunit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:5330-5334(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Liver;
RA   Huh T.L., Chi Y.T., Casazza J.P., Veech R.L., Song B.J.;
RL   Submitted (APR-1990) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3034892;
RA   Dahl H.-H.M., Hunt S.M., Hutchison W.M., Brown G.K.;
RT   "The human pyruvate dehydrogenase complex. Isolation of cDNA clones
RT   for the E1 alpha subunit, sequence analysis, and characterization of
RT   the mRNA.";
RL   J. Biol. Chem. 262:7398-7403(1987).
RN   [5]
RP   SEQUENCE REVISION.
RX   PubMed=2745444;
RA   Maragos C., Hutchinson W.M., Hayasaki K., Brown G.K., Dahl H.-H.M.;
RT   "Structural organization of the gene for the E1 alpha subunit of the
RT   human pyruvate dehydrogenase complex.";
RL   J. Biol. Chem. 264:12294-12298(1989).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2828359;
RA   de Meirleir L., MacKay N., Wah A.M.L.H., Robinson B.H.;
RT   "Isolation of a full-length complementary DNA coding for human E1
RT   alpha subunit of the pyruvate dehydrogenase complex.";
RL   J. Biol. Chem. 263:1991-1995(1988).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3422424; DOI=10.1073/pnas.85.1.41;
RA   Koike K., Ohta S., Urata Y., Kagawa Y., Koike M.;
RT   "Cloning and sequencing of cDNAs encoding alpha and beta subunits of
RT   human pyruvate dehydrogenase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:41-45(1988).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RA   Okajima K.;
RL   Submitted (MAY-2007) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LEU-282.
RC   TISSUE=Dermoid cancer;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   PROTEIN SEQUENCE OF 31-37, AND TRANSIT PEPTIDE.
RX   PubMed=23146587; DOI=10.1016/j.ab.2012.10.040;
RA   Candat A., Poupart P., Andrieu J.P., Chevrollier A., Reynier P.,
RA   Rogniaux H., Avelange-Macherel M.H., Macherel D.;
RT   "Experimental determination of organelle targeting-peptide cleavage
RT   sites using transient expression of green fluorescent protein
RT   translational fusions.";
RL   Anal. Biochem. 434:44-51(2013).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 202-336, AND VARIANT LEU-282.
RX   PubMed=10077682; DOI=10.1073/pnas.96.6.3320;
RA   Harris E.E., Hey J.;
RT   "X chromosome evidence for ancient human histories.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:3320-3324(1999).
RN   [16]
RP   INVOLVEMENT IN PDHAD.
RX   PubMed=1338114; DOI=10.1007/BF01800220;
RA   Ito M., Huq A.H., Naito E., Saijo T., Takeda E., Kuroda Y.;
RT   "Mutation of E1 alpha gene in a female patient with pyruvate
RT   dehydrogenase deficiency due to rapid degradation of E1 protein.";
RL   J. Inherit. Metab. Dis. 15:848-856(1992).
RN   [17]
RP   CATALYTIC ACTIVITY, FUNCTION, ENZYME REGULATION, AND MUTAGENESIS OF
RP   SER-232; SER-293 AND SER-300.
RX   PubMed=7782287; DOI=10.1074/jbc.270.24.14297;
RA   Korotchkina L.G., Patel M.S.;
RT   "Mutagenesis studies of the phosphorylation sites of recombinant human
RT   pyruvate dehydrogenase. Site-specific regulation.";
RL   J. Biol. Chem. 270:14297-14304(1995).
RN   [18]
RP   PHOSPHORYLATION AT SER-232; SER-293 AND SER-300.
RX   PubMed=11486000; DOI=10.1074/jbc.M103069200;
RA   Korotchkina L.G., Patel M.S.;
RT   "Site specificity of four pyruvate dehydrogenase kinase isoenzymes
RT   toward the three phosphorylation sites of human pyruvate
RT   dehydrogenase.";
RL   J. Biol. Chem. 276:37223-37229(2001).
RN   [19]
RP   SUBUNIT.
RX   PubMed=14638692; DOI=10.1074/jbc.M308172200;
RA   Hiromasa Y., Fujisawa T., Aso Y., Roche T.E.;
RT   "Organization of the cores of the mammalian pyruvate dehydrogenase
RT   complex formed by E2 and E2 plus the E3-binding protein and their
RT   capacities to bind the E1 and E3 components.";
RL   J. Biol. Chem. 279:6921-6933(2004).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [25]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-321, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) IN COMPLEX WITH THIAMINE
RP   PYROPHOSPHATE, AND COFACTOR.
RX   PubMed=12651851; DOI=10.1074/jbc.M300339200;
RA   Ciszak E.M., Korotchkina L.G., Dominiak P.M., Sidhu S., Patel M.S.;
RT   "Structural basis for flip-flop action of thiamin pyrophosphate-
RT   dependent enzymes revealed by human pyruvate dehydrogenase.";
RL   J. Biol. Chem. 278:21240-21246(2003).
RN   [33]
RP   REVIEW ON VARIANTS.
RX   PubMed=1301207; DOI=10.1002/humu.1380010203;
RA   Dahl H.-H.M., Brown G.K., Brown R.M., Hansen L.L., Kerr D.S.,
RA   Wexler I.D., Patel M.S., de Meirleir L., Lissens W., Chun K.,
RA   McKay N., Robinson B.H.;
RT   "Mutations and polymorphisms in the pyruvate dehydrogenase E1 alpha
RT   gene.";
RL   Hum. Mutat. 1:97-102(1992).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 30-390, ENZYME REGULATION,
RP   CATALYTIC ACTIVITY, MUTAGENESIS OF SER-293, AND PHOSPHORYLATION AT
RP   SER-293.
RX   PubMed=17474719; DOI=10.1021/bi700083z;
RA   Seifert F., Ciszak E., Korotchkina L., Golbik R., Spinka M.,
RA   Dominiak P., Sidhu S., Brauer J., Patel M.S., Tittmann K.;
RT   "Phosphorylation of serine 264 impedes active site accessibility in
RT   the E1 component of the human pyruvate dehydrogenase multienzyme
RT   complex.";
RL   Biochemistry 46:6277-6287(2007).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.98 ANGSTROMS) OF 30-390 IN COMPLEX WITH PDHB,
RP   SUBUNIT, FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ENZYME REGULATION,
RP   AND PHOSPHORYLATION AT SER-293 AND SER-300 BY PDK4.
RX   PubMed=19081061; DOI=10.1016/j.str.2008.10.010;
RA   Kato M., Wynn R.M., Chuang J.L., Tso S.C., Machius M., Li J.,
RA   Chuang D.T.;
RT   "Structural basis for inactivation of the human pyruvate dehydrogenase
RT   complex by phosphorylation: role of disordered phosphorylation
RT   loops.";
RL   Structure 16:1849-1859(2008).
RN   [36]
RP   VARIANTS PDHAD LYS-313 DEL AND HIS-378.
RX   PubMed=1909401; DOI=10.1007/BF01800586;
RA   Hansen L.L., Brown G.K., Kirby D.M., Dahl H.-H.M.;
RT   "Characterization of the mutations in three patients with pyruvate
RT   dehydrogenase E1 alpha deficiency.";
RL   J. Inherit. Metab. Dis. 14:140-151(1991).
RN   [37]
RP   VARIANT PDHAD ASP-SER-TYR-ARG-THR-ARG-GLU-305 INS.
RX   PubMed=1551669; DOI=10.1007/BF02265291;
RA   De Meirleir L., Lissens W., Vamos E., Liebaers I.;
RT   "Pyruvate dehydrogenase (PDH) deficiency caused by a 21-base pair
RT   insertion mutation in the E1 alpha subunit.";
RL   Hum. Genet. 88:649-652(1992).
RN   [38]
RP   VARIANT PDHAD CYS-302.
RX   PubMed=1293379; DOI=10.1007/BF01800219;
RA   Dahl H.-H.M., Hansen L.L., Brown R.M., Danks D.M., Rogers J.G.,
RA   Brown G.K.;
RT   "X-linked pyruvate dehydrogenase E1 alpha subunit deficiency in
RT   heterozygous females: variable manifestation of the same mutation.";
RL   J. Inherit. Metab. Dis. 15:835-847(1992).
RN   [39]
RP   VARIANT PDHAD ALA-258.
RX   PubMed=8498846; DOI=10.1002/ana.410330616;
RA   Matthews P.M., Marchington D.R., Squier M., Land J., Brown R.M.,
RA   Brown G.K.;
RT   "Molecular genetic characterization of an X-linked form of Leigh's
RT   syndrome.";
RL   Ann. Neurol. 33:652-655(1993).
RN   [40]
RP   VARIANTS PDHAD MET-167; THR-199; ALA-231; GLY-263 AND LEU-292.
RX   PubMed=8504306; DOI=10.1093/hmg/2.4.449;
RA   Chun K., McKay N., Petrova-Benedict R., Robinson B.H.;
RT   "Mutations in the X-linked E1 alpha subunit of pyruvate dehydrogenase
RT   leading to deficiency of the pyruvate dehydrogenase complex.";
RL   Hum. Mol. Genet. 2:449-454(1993).
RN   [41]
RP   VARIANTS PDHAD ASN-243; ASN-315 AND HIS-378, AND VARIANT LEU-282.
RX   PubMed=8032855; DOI=10.1093/brain/117.3.435;
RA   Matthews P.M., Brown R.M., Otero L.J., Marchington D.R., LeGris M.,
RA   Howes R., Meadows L.S., Shevell M., Scriver C.R., Brown G.K.;
RT   "Pyruvate dehydrogenase deficiency. Clinical presentation and
RT   molecular genetic characterization of five new patients.";
RL   Brain 117:435-443(1994).
RN   [42]
RP   VARIANT PDHAD PRO-PRO-HIS-SER-TYR-ARG-THR-ARG-GLU-GLU-ILE-307 INS.
RX   PubMed=7545958; DOI=10.1093/hmg/3.6.1021;
RA   Hansen L.L., Horn N., Dahl H.-H.M., Kruse T.A.;
RT   "Pyruvate dehydrogenase deficiency caused by a 33 base pair
RT   duplication in the PDH E1 alpha subunit.";
RL   Hum. Mol. Genet. 3:1021-1022(1994).
RN   [43]
RP   VARIANT PDHAD LEU-205.
RX   PubMed=8199595; DOI=10.1002/humu.1380030210;
RA   Dahl H.-H.M., Brown G.K.;
RT   "Pyruvate dehydrogenase deficiency in a male caused by a point
RT   mutation (F205L) in the E1 alpha subunit.";
RL   Hum. Mutat. 3:152-155(1994).
RN   [44]
RP   VARIANT PDHAD GLN-263.
RX   PubMed=7967473; DOI=10.1007/BF00711616;
RA   Awata H., Endo F., Tanoue A., Kitano A., Matsuda I.;
RT   "Characterization of a point mutation in the pyruvate dehydrogenase E1
RT   alpha gene from two boys with primary lactic acidaemia.";
RL   J. Inherit. Metab. Dis. 17:189-195(1994).
RN   [45]
RP   VARIANTS PDHAD CYS-72; LEU-205; GLY-263; ARG-311 DEL AND HIS-378.
RX   PubMed=7887409;
RA   Chun K., MacKay N., Petrova-Benedict R., Federico A., Fois A.,
RA   Cole D.E.C., Robertson E., Robinson B.H.;
RT   "Mutations in the X-linked E1 alpha subunit of pyruvate dehydrogenase:
RT   exon skipping, insertion of duplicate sequence, and missense mutations
RT   leading to the deficiency of the pyruvate dehydrogenase complex.";
RL   Am. J. Hum. Genet. 56:558-569(1995).
RN   [46]
RP   VARIANT PDHAD PRO-10.
RX   PubMed=7573035;
RA   Takakubo F., Cartwright P., Hoogenraad N., Thorburn D.R., Collins F.,
RA   Lithgow T., Dahl H.-H.M.;
RT   "An amino acid substitution in the pyruvate dehydrogenase E1 alpha
RT   gene, affecting mitochondrial import of the precursor protein.";
RL   Am. J. Hum. Genet. 57:772-780(1995).
RN   [47]
RP   VARIANT PDHAD LEU-217.
RX   PubMed=7757088; DOI=10.1093/hmg/4.2.315;
RA   Hemalatha S.G., Kerr D.S., Wexler I.D., Lusk M.M., Kaung M., Du Y.,
RA   Kolli M., Schelper R.L., Patel M.S.;
RT   "Pyruvate dehydrogenase complex deficiency due to a point mutation
RT   (P188L) within the thiamine pyrophosphate binding loop of the E1 alpha
RT   subunit.";
RL   Hum. Mol. Genet. 4:315-318(1995).
RN   [48]
RP   VARIANTS PDHAD CYS-72; ASP-113; ARG-162; GLY-263; HIS-288 AND CYS-302.
RX   PubMed=8664900;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:1<46::AID-HUMU6>3.3.CO;2-2;
RA   Lissens W., de Meirleir L., Seneca S., Benelli C., Marsac C.,
RA   Poll-The B.T., Briones P., Ruitenbeek W., van Diggelen O., Chaigne D.,
RA   Ramaekers V., Liebaers I.;
RT   "Mutation analysis of the pyruvate dehydrogenase E1 alpha gene in
RT   eight patients with a pyruvate dehydrogenase complex deficiency.";
RL   Hum. Mutat. 7:46-51(1996).
RN   [49]
RP   VARIANTS PDHAD VAL-210 AND ARG-311 DEL.
RX   PubMed=8844217;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:2<180::AID-HUMU11>3.3.CO;2-O;
RA   Tripatara A., Kerr D.S., Lusk M.M., Kolli M., Tan J., Patel M.S.;
RT   "Three new mutations of the pyruvate dehydrogenase alpha subunit: a
RT   point mutation (M181V), 3 bp deletion (-R282), and 16 bp
RT   insertion/frameshift (K358SVS-->TVDQS).";
RL   Hum. Mutat. 8:180-182(1996).
RN   [50]
RP   VARIANT PDHAD GLY-263.
RX   PubMed=9266390; DOI=10.1023/A:1005305614374;
RA   Naito E., Ito M., Yokota I., Saijo T., Matsuda J., Osaka H.,
RA   Kimura S., Kuroda Y.;
RT   "Biochemical and molecular analysis of an X-linked case of Leigh
RT   syndrome associated with thiamin-responsive pyruvate dehydrogenase
RT   deficiency.";
RL   J. Inherit. Metab. Dis. 20:539-548(1997).
RN   [51]
RP   VARIANTS PDHAD CYS-302 AND HIS-302.
RX   PubMed=9671272;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:2<114::AID-HUMU6>3.0.CO;2-#;
RA   Otero L.J., Brown R.M., Brown G.K.;
RT   "Arginine 302 mutations in the pyruvate dehydrogenase E1alpha subunit
RT   gene: identification of further patients and in vitro demonstration of
RT   pathogenicity.";
RL   Hum. Mutat. 12:114-121(1998).
RN   [52]
RP   VARIANT THR-136.
RX   PubMed=23033978; DOI=10.1056/NEJMoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P.,
RA   Gilissen C., del Rosario M., Hoischen A., Scheffer H., de Vries B.B.,
RA   Brunner H.G., Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
RN   [53]
RP   VARIANT PDHAD CYS-302.
RX   PubMed=27864847; DOI=10.1002/humu.23149;
RG   Clinical Study Group;
RA   Parrini E., Marini C., Mei D., Galuppi A., Cellini E., Pucatti D.,
RA   Chiti L., Rutigliano D., Bianchini C., Virdo S., De Vita D.,
RA   Bigoni S., Barba C., Mari F., Montomoli M., Pisano T., Rosati A.,
RA   Guerrini R.;
RT   "Diagnostic targeted resequencing in 349 patients with drug-resistant
RT   pediatric epilepsies identifies causative mutations in 30 different
RT   genes.";
RL   Hum. Mutat. 38:216-225(2017).
CC   -!- FUNCTION: The pyruvate dehydrogenase complex catalyzes the overall
CC       conversion of pyruvate to acetyl-CoA and CO(2), and thereby links
CC       the glycolytic pathway to the tricarboxylic cycle.
CC       {ECO:0000269|PubMed:19081061, ECO:0000269|PubMed:7782287}.
CC   -!- CATALYTIC ACTIVITY: Pyruvate + [dihydrolipoyllysine-residue
CC       acetyltransferase] lipoyllysine = [dihydrolipoyllysine-residue
CC       acetyltransferase] S-acetyldihydrolipoyllysine + CO(2).
CC       {ECO:0000269|PubMed:17474719, ECO:0000269|PubMed:19081061,
CC       ECO:0000269|PubMed:7782287}.
CC   -!- COFACTOR:
CC       Name=thiamine diphosphate; Xref=ChEBI:CHEBI:58937;
CC         Evidence={ECO:0000269|PubMed:12651851,
CC         ECO:0000269|PubMed:19081061};
CC   -!- ENZYME REGULATION: Pyruvate dehydrogenase activity is inhibited by
CC       phosphorylation of PDHA1; it is reactivated by dephosphorylation.
CC       {ECO:0000269|PubMed:17474719, ECO:0000269|PubMed:19081061,
CC       ECO:0000269|PubMed:7782287}.
CC   -!- SUBUNIT: Heterotetramer of two PDHA1 and two PDHB subunits. The
CC       heterotetramer interacts with DLAT, and is part of the multimeric
CC       pyruvate dehydrogenase complex that contains multiple copies of
CC       pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase
CC       (DLAT, E2) and lipoamide dehydrogenase (DLD, E3). These subunits
CC       are bound to an inner core composed of about 48 DLAT and 12 PDHX
CC       molecules. {ECO:0000269|PubMed:12651851,
CC       ECO:0000269|PubMed:14638692, ECO:0000269|PubMed:19081061}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P08559-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08559-2; Sequence=VSP_042569;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P08559-3; Sequence=VSP_042570;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=P08559-4; Sequence=VSP_043363;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- PTM: Phosphorylation at Ser-232, Ser-293 and Ser-300 by PDK family
CC       kinases inactivates the enzyme; for this phosphorylation at a
CC       single site is sufficient. Dephosphorylation at all three sites,
CC       i.e. at Ser-232, Ser-293 and Ser-300, is required for
CC       reactivation. {ECO:0000269|PubMed:11486000,
CC       ECO:0000269|PubMed:17474719, ECO:0000269|PubMed:19081061}.
CC   -!- PTM: Acetylation alters the phosphorylation pattern. Deacetylated
CC       by SIRT3 (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Pyruvate dehydrogenase E1-alpha deficiency (PDHAD)
CC       [MIM:312170]: An enzymatic defect causing primary lactic acidosis
CC       in children. It is associated with a broad clinical spectrum
CC       ranging from fatal lactic acidosis in the newborn to chronic
CC       neurologic dysfunction with structural abnormalities in the
CC       central nervous system without systemic acidosis.
CC       {ECO:0000269|PubMed:1293379, ECO:0000269|PubMed:1338114,
CC       ECO:0000269|PubMed:1551669, ECO:0000269|PubMed:1909401,
CC       ECO:0000269|PubMed:27864847, ECO:0000269|PubMed:7545958,
CC       ECO:0000269|PubMed:7573035, ECO:0000269|PubMed:7757088,
CC       ECO:0000269|PubMed:7887409, ECO:0000269|PubMed:7967473,
CC       ECO:0000269|PubMed:8032855, ECO:0000269|PubMed:8199595,
CC       ECO:0000269|PubMed:8498846, ECO:0000269|PubMed:8504306,
CC       ECO:0000269|PubMed:8664900, ECO:0000269|PubMed:8844217,
CC       ECO:0000269|PubMed:9266390, ECO:0000269|PubMed:9671272}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA60055.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAB59581.1; Type=Frameshift; Positions=106, 175; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D90084; BAA14121.1; -; Genomic_DNA.
DR   EMBL; M24848; AAA36533.1; -; mRNA.
DR   EMBL; X52709; CAA36933.1; -; mRNA.
DR   EMBL; X52710; CAA36934.1; -; mRNA.
DR   EMBL; M27257; AAA60051.1; -; Genomic_DNA.
DR   EMBL; M29155; AAA60051.1; JOINED; Genomic_DNA.
DR   EMBL; M29156; AAA60051.1; JOINED; Genomic_DNA.
DR   EMBL; M29157; AAA60051.1; JOINED; Genomic_DNA.
DR   EMBL; M29158; AAA60051.1; JOINED; Genomic_DNA.
DR   EMBL; M29159; AAA60051.1; JOINED; Genomic_DNA.
DR   EMBL; M29160; AAA60051.1; JOINED; Genomic_DNA.
DR   EMBL; M29161; AAA60051.1; JOINED; Genomic_DNA.
DR   EMBL; M29162; AAA60051.1; JOINED; Genomic_DNA.
DR   EMBL; M29163; AAA60051.1; JOINED; Genomic_DNA.
DR   EMBL; M29164; AAA60051.1; JOINED; Genomic_DNA.
DR   EMBL; L13318; AAA60227.1; -; mRNA.
DR   EMBL; J03503; AAA60055.1; ALT_INIT; mRNA.
DR   EMBL; J03575; AAA60050.1; -; mRNA.
DR   EMBL; L48690; AAB59581.1; ALT_FRAME; mRNA.
DR   EMBL; EF590117; ABQ59099.1; -; mRNA.
DR   EMBL; AK293250; BAH11476.1; -; mRNA.
DR   EMBL; AK296457; BAH12361.1; -; mRNA.
DR   EMBL; AK312263; BAG35194.1; -; mRNA.
DR   EMBL; AK296341; BAH12323.1; -; mRNA.
DR   EMBL; AK222740; BAD96460.1; -; mRNA.
DR   EMBL; AL732326; CAI41291.1; -; Genomic_DNA.
DR   EMBL; CH471074; EAW98960.1; -; Genomic_DNA.
DR   EMBL; BC002406; AAH02406.1; -; mRNA.
DR   EMBL; AF125053; AAD23841.1; -; Genomic_DNA.
DR   EMBL; AF125054; AAD23842.1; -; Genomic_DNA.
DR   EMBL; AF125055; AAD23843.1; -; Genomic_DNA.
DR   EMBL; AF125056; AAD23844.1; -; Genomic_DNA.
DR   EMBL; AF125057; AAD23845.1; -; Genomic_DNA.
DR   EMBL; AF125058; AAD23846.1; -; Genomic_DNA.
DR   EMBL; AF125059; AAD23847.1; -; Genomic_DNA.
DR   EMBL; AF125060; AAD23848.1; -; Genomic_DNA.
DR   EMBL; AF125061; AAD23849.1; -; Genomic_DNA.
DR   EMBL; AF125062; AAD23850.1; -; Genomic_DNA.
DR   EMBL; AF125063; AAD23851.1; -; Genomic_DNA.
DR   EMBL; AF125064; AAD23852.1; -; Genomic_DNA.
DR   EMBL; AF125065; AAD23853.1; -; Genomic_DNA.
DR   EMBL; AF125066; AAD23854.1; -; Genomic_DNA.
DR   EMBL; AF125067; AAD23855.1; -; Genomic_DNA.
DR   EMBL; AF125068; AAD23856.1; -; Genomic_DNA.
DR   EMBL; AF125069; AAD23857.1; -; Genomic_DNA.
DR   EMBL; AF125070; AAD23858.1; -; Genomic_DNA.
DR   EMBL; AF125071; AAD23859.1; -; Genomic_DNA.
DR   EMBL; AF125072; AAD23860.1; -; Genomic_DNA.
DR   EMBL; AF125073; AAD23861.1; -; Genomic_DNA.
DR   EMBL; AF125074; AAD23862.1; -; Genomic_DNA.
DR   EMBL; AF125075; AAD23863.1; -; Genomic_DNA.
DR   EMBL; AF125076; AAD23864.1; -; Genomic_DNA.
DR   EMBL; AF125078; AAD23866.1; -; Genomic_DNA.
DR   EMBL; AF125079; AAD23867.1; -; Genomic_DNA.
DR   EMBL; AF125080; AAD23868.1; -; Genomic_DNA.
DR   EMBL; AF125081; AAD23869.1; -; Genomic_DNA.
DR   EMBL; AF125082; AAD23870.1; -; Genomic_DNA.
DR   EMBL; AF125083; AAD23871.1; -; Genomic_DNA.
DR   EMBL; AF125084; AAD23872.1; -; Genomic_DNA.
DR   EMBL; AF125085; AAD23873.1; -; Genomic_DNA.
DR   EMBL; AF125086; AAD23874.1; -; Genomic_DNA.
DR   EMBL; AF125087; AAD23875.1; -; Genomic_DNA.
DR   EMBL; AF125088; AAD23876.1; -; Genomic_DNA.
DR   CCDS; CCDS14192.1; -. [P08559-1]
DR   CCDS; CCDS55380.1; -. [P08559-4]
DR   CCDS; CCDS55381.1; -. [P08559-2]
DR   CCDS; CCDS55382.1; -. [P08559-3]
DR   PIR; JQ0770; DEHUPA.
DR   RefSeq; NP_000275.1; NM_000284.3. [P08559-1]
DR   RefSeq; NP_001166925.1; NM_001173454.1. [P08559-4]
DR   RefSeq; NP_001166926.1; NM_001173455.1. [P08559-2]
DR   RefSeq; NP_001166927.1; NM_001173456.1. [P08559-3]
DR   UniGene; Hs.530331; -.
DR   PDB; 1NI4; X-ray; 1.95 A; A/C=30-390.
DR   PDB; 2OZL; X-ray; 1.90 A; A/C=30-390.
DR   PDB; 3EXE; X-ray; 1.98 A; A/C/E/G=30-390.
DR   PDB; 3EXF; X-ray; 3.00 A; A/C/E/G=30-390.
DR   PDB; 3EXG; X-ray; 3.01 A; 1/3/5/A/C/E/G/I/K/M/O/Q/S/U/W/Y=30-390.
DR   PDB; 3EXH; X-ray; 2.44 A; A/C/E/G=30-390.
DR   PDB; 3EXI; X-ray; 2.20 A; A=30-390.
DR   PDBsum; 1NI4; -.
DR   PDBsum; 2OZL; -.
DR   PDBsum; 3EXE; -.
DR   PDBsum; 3EXF; -.
DR   PDBsum; 3EXG; -.
DR   PDBsum; 3EXH; -.
DR   PDBsum; 3EXI; -.
DR   ProteinModelPortal; P08559; -.
DR   SMR; P08559; -.
DR   BioGrid; 111186; 52.
DR   DIP; DIP-37652N; -.
DR   IntAct; P08559; 19.
DR   MINT; MINT-3006251; -.
DR   DrugBank; DB00157; NADH.
DR   iPTMnet; P08559; -.
DR   PhosphoSitePlus; P08559; -.
DR   SwissPalm; P08559; -.
DR   BioMuta; PDHA1; -.
DR   DMDM; 129063; -.
DR   REPRODUCTION-2DPAGE; IPI00306301; -.
DR   UCD-2DPAGE; P08559; -.
DR   EPD; P08559; -.
DR   MaxQB; P08559; -.
DR   PeptideAtlas; P08559; -.
DR   PRIDE; P08559; -.
DR   TopDownProteomics; P08559-3; -. [P08559-3]
DR   TopDownProteomics; P08559-4; -. [P08559-4]
DR   DNASU; 5160; -.
DR   Ensembl; ENST00000379806; ENSP00000369134; ENSG00000131828. [P08559-4]
DR   Ensembl; ENST00000422285; ENSP00000394382; ENSG00000131828. [P08559-1]
DR   Ensembl; ENST00000540249; ENSP00000440761; ENSG00000131828. [P08559-3]
DR   Ensembl; ENST00000545074; ENSP00000438550; ENSG00000131828. [P08559-2]
DR   GeneID; 5160; -.
DR   KEGG; hsa:5160; -.
DR   UCSC; uc004czg.5; human. [P08559-1]
DR   CTD; 5160; -.
DR   DisGeNET; 5160; -.
DR   GeneCards; PDHA1; -.
DR   HGNC; HGNC:8806; PDHA1.
DR   HPA; HPA047487; -.
DR   HPA; HPA047864; -.
DR   HPA; HPA063053; -.
DR   MalaCards; PDHA1; -.
DR   MIM; 300502; gene.
DR   MIM; 312170; phenotype.
DR   neXtProt; NX_P08559; -.
DR   OpenTargets; ENSG00000131828; -.
DR   Orphanet; 70474; Leigh syndrome with cardiomyopathy.
DR   Orphanet; 79243; Pyruvate dehydrogenase E1-alpha deficiency.
DR   PharmGKB; PA33150; -.
DR   GeneTree; ENSGT00530000063174; -.
DR   HOGENOM; HOG000281336; -.
DR   HOVERGEN; HBG001863; -.
DR   InParanoid; P08559; -.
DR   KO; K00161; -.
DR   OMA; WMYQKML; -.
DR   OrthoDB; EOG091G0966; -.
DR   PhylomeDB; P08559; -.
DR   TreeFam; TF300742; -.
DR   BioCyc; MetaCyc:HS05573-MONOMER; -.
DR   BRENDA; 1.2.4.1; 2681.
DR   Reactome; R-HSA-204174; Regulation of pyruvate dehydrogenase (PDH) complex.
DR   Reactome; R-HSA-389661; Glyoxylate metabolism and glycine degradation.
DR   Reactome; R-HSA-5362517; Signaling by Retinoic Acid.
DR   Reactome; R-HSA-70268; Pyruvate metabolism.
DR   SABIO-RK; P08559; -.
DR   SIGNOR; P08559; -.
DR   ChiTaRS; PDHA1; human.
DR   EvolutionaryTrace; P08559; -.
DR   GeneWiki; Pyruvate_dehydrogenase_(lipoamide)_alpha_1; -.
DR   GenomeRNAi; 5160; -.
DR   PRO; PR:P08559; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000131828; -.
DR   CleanEx; HS_PDHA1; -.
DR   ExpressionAtlas; P08559; baseline and differential.
DR   Genevisible; P08559; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0045254; C:pyruvate dehydrogenase complex; IDA:UniProtKB.
DR   GO; GO:0004739; F:pyruvate dehydrogenase (acetyl-transferring) activity; IEA:UniProtKB-EC.
DR   GO; GO:0034604; F:pyruvate dehydrogenase (NAD+) activity; IEA:Ensembl.
DR   GO; GO:0004738; F:pyruvate dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0006086; P:acetyl-CoA biosynthetic process from pyruvate; IDA:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0046487; P:glyoxylate metabolic process; TAS:Reactome.
DR   GO; GO:0061732; P:mitochondrial acetyl-CoA biosynthetic process from pyruvate; IEA:Ensembl.
DR   GO; GO:0006090; P:pyruvate metabolic process; TAS:Reactome.
DR   GO; GO:0010510; P:regulation of acetyl-CoA biosynthetic process from pyruvate; TAS:Reactome.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IDA:UniProtKB.
DR   InterPro; IPR001017; DH_E1.
DR   InterPro; IPR017597; Pyrv_DH_E1_asu_subgrp-y.
DR   InterPro; IPR029061; THDP-binding.
DR   Pfam; PF00676; E1_dh; 1.
DR   SUPFAM; SSF52518; SSF52518; 1.
DR   TIGRFAMs; TIGR03182; PDH_E1_alph_y; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Carbohydrate metabolism; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Glucose metabolism; Leigh syndrome; Mitochondrion;
KW   Oxidoreductase; Phosphoprotein; Polymorphism; Pyruvate;
KW   Reference proteome; Thiamine pyrophosphate; Transit peptide;
KW   Tricarboxylic acid cycle.
FT   TRANSIT       1     30       Mitochondrion.
FT                                {ECO:0000269|PubMed:23146587}.
FT   CHAIN        31    390       Pyruvate dehydrogenase E1 component
FT                                subunit alpha, somatic form,
FT                                mitochondrial.
FT                                /FTId=PRO_0000020440.
FT   MOD_RES      63     63       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P35486}.
FT   MOD_RES      63     63       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P35486}.
FT   MOD_RES     231    231       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P26284}.
FT   MOD_RES     232    232       Phosphoserine; by PDK1.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:11486000}.
FT   MOD_RES     244    244       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P35486}.
FT   MOD_RES     244    244       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P35486}.
FT   MOD_RES     277    277       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P35486}.
FT   MOD_RES     293    293       Phosphoserine; by PDK1, PDK2, PDK3 and
FT                                PDK4. {ECO:0000269|PubMed:11486000,
FT                                ECO:0000269|PubMed:17474719,
FT                                ECO:0000269|PubMed:19081061}.
FT   MOD_RES     295    295       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P35486}.
FT   MOD_RES     300    300       Phosphoserine; by PDK1, PDK2, PDK3 and
FT                                PDK4. {ECO:0000269|PubMed:11486000,
FT                                ECO:0000269|PubMed:19081061}.
FT   MOD_RES     301    301       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P35486}.
FT   MOD_RES     313    313       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P35486}.
FT   MOD_RES     313    313       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P35486}.
FT   MOD_RES     321    321       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     336    336       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P35486}.
FT   MOD_RES     385    385       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P35486}.
FT   VAR_SEQ      19     19       P -> PRHGLATLPSLVSISRLKQSSHLGLPKCWDYSHSLK
FT                                TRQ (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.8}.
FT                                /FTId=VSP_043363.
FT   VAR_SEQ      96     96       G -> GQFLLPLT (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042569.
FT   VAR_SEQ     170    200       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042570.
FT   VARIANT      10     10       R -> P (in PDHAD; affects mitochondrial
FT                                import of precursor protein;
FT                                dbSNP:rs137853257).
FT                                {ECO:0000269|PubMed:7573035}.
FT                                /FTId=VAR_010238.
FT   VARIANT      72     72       R -> C (in PDHAD; dbSNP:rs863224148).
FT                                {ECO:0000269|PubMed:7887409,
FT                                ECO:0000269|PubMed:8664900}.
FT                                /FTId=VAR_004949.
FT   VARIANT     113    113       H -> D (in PDHAD).
FT                                {ECO:0000269|PubMed:8664900}.
FT                                /FTId=VAR_004950.
FT   VARIANT     136    136       A -> T (probable disease-associated
FT                                mutation found in a patient with moderate
FT                                developmental delay, mild dysmorphism and
FT                                mildly elevated serum lactate;
FT                                dbSNP:rs138727886).
FT                                {ECO:0000269|PubMed:23033978}.
FT                                /FTId=VAR_069381.
FT   VARIANT     162    162       G -> R (in PDHAD; dbSNP:rs866868610).
FT                                {ECO:0000269|PubMed:8664900}.
FT                                /FTId=VAR_004951.
FT   VARIANT     167    167       V -> M (in PDHAD).
FT                                {ECO:0000269|PubMed:8504306}.
FT                                /FTId=VAR_004952.
FT   VARIANT     199    199       A -> T (in PDHAD).
FT                                {ECO:0000269|PubMed:8504306}.
FT                                /FTId=VAR_004953.
FT   VARIANT     205    205       F -> L (in PDHAD; dbSNP:rs137853254).
FT                                {ECO:0000269|PubMed:7887409,
FT                                ECO:0000269|PubMed:8199595}.
FT                                /FTId=VAR_004954.
FT   VARIANT     210    210       M -> V (in PDHAD; dbSNP:rs794727843).
FT                                {ECO:0000269|PubMed:8844217}.
FT                                /FTId=VAR_004955.
FT   VARIANT     217    217       P -> L (in PDHAD).
FT                                {ECO:0000269|PubMed:7757088}.
FT                                /FTId=VAR_004956.
FT   VARIANT     231    231       T -> A (in PDHAD).
FT                                {ECO:0000269|PubMed:8504306}.
FT                                /FTId=VAR_004957.
FT   VARIANT     243    243       Y -> N (in PDHAD; dbSNP:rs137853255).
FT                                {ECO:0000269|PubMed:8032855}.
FT                                /FTId=VAR_021053.
FT   VARIANT     258    258       D -> A (in PDHAD; dbSNP:rs137853253).
FT                                {ECO:0000269|PubMed:8498846}.
FT                                /FTId=VAR_004958.
FT   VARIANT     263    263       R -> G (in PDHAD; dbSNP:rs28936081).
FT                                {ECO:0000269|PubMed:7887409,
FT                                ECO:0000269|PubMed:8504306,
FT                                ECO:0000269|PubMed:8664900,
FT                                ECO:0000269|PubMed:9266390}.
FT                                /FTId=VAR_004959.
FT   VARIANT     263    263       R -> Q (in PDHAD).
FT                                {ECO:0000269|PubMed:7967473}.
FT                                /FTId=VAR_004960.
FT   VARIANT     282    282       M -> L (in dbSNP:rs2229137).
FT                                {ECO:0000269|PubMed:10077682,
FT                                ECO:0000269|PubMed:8032855,
FT                                ECO:0000269|Ref.10}.
FT                                /FTId=VAR_021054.
FT   VARIANT     288    288       R -> H (in PDHAD; dbSNP:rs137853258).
FT                                {ECO:0000269|PubMed:8664900}.
FT                                /FTId=VAR_021055.
FT   VARIANT     292    292       H -> L (in PDHAD).
FT                                {ECO:0000269|PubMed:8504306}.
FT                                /FTId=VAR_004961.
FT   VARIANT     302    302       R -> C (in PDHAD; loss of activity;
FT                                common mutation; dbSNP:rs137853252).
FT                                {ECO:0000269|PubMed:1293379,
FT                                ECO:0000269|PubMed:27864847,
FT                                ECO:0000269|PubMed:8664900,
FT                                ECO:0000269|PubMed:9671272}.
FT                                /FTId=VAR_004962.
FT   VARIANT     302    302       R -> H (in PDHAD).
FT                                {ECO:0000269|PubMed:9671272}.
FT                                /FTId=VAR_004963.
FT   VARIANT     305    305       E -> EDSYRTRE (in PDHAD).
FT                                {ECO:0000269|PubMed:1551669}.
FT                                /FTId=VAR_020908.
FT   VARIANT     307    307       I -> IPPHSYRTREEI (in PDHAD).
FT                                {ECO:0000269|PubMed:7545958}.
FT                                /FTId=VAR_020909.
FT   VARIANT     311    311       Missing (in PDHAD).
FT                                {ECO:0000269|PubMed:7887409,
FT                                ECO:0000269|PubMed:8844217}.
FT                                /FTId=VAR_004964.
FT   VARIANT     313    313       Missing (in PDHAD).
FT                                {ECO:0000269|PubMed:1909401}.
FT                                /FTId=VAR_004965.
FT   VARIANT     315    315       D -> N (in PDHAD; dbSNP:rs28935187).
FT                                {ECO:0000269|PubMed:8032855}.
FT                                /FTId=VAR_021056.
FT   VARIANT     333    333       E -> D (in dbSNP:rs2228067).
FT                                /FTId=VAR_050436.
FT   VARIANT     378    378       R -> H (in PDHAD; dbSNP:rs137853250).
FT                                {ECO:0000269|PubMed:1909401,
FT                                ECO:0000269|PubMed:7887409,
FT                                ECO:0000269|PubMed:8032855}.
FT                                /FTId=VAR_004966.
FT   MUTAGEN     232    232       S->A: Abolishes inactivation by
FT                                phosphorylation; when associated with A-
FT                                293 and A-300.
FT                                {ECO:0000269|PubMed:7782287}.
FT   MUTAGEN     293    293       S->A: Reduces enzyme activity. Abolishes
FT                                inactivation by phosphorylation; when
FT                                associated with A-232 and A-300.
FT                                {ECO:0000269|PubMed:17474719,
FT                                ECO:0000269|PubMed:7782287}.
FT   MUTAGEN     293    293       S->E: Interferes with substrate binding.
FT                                {ECO:0000269|PubMed:17474719,
FT                                ECO:0000269|PubMed:7782287}.
FT   MUTAGEN     300    300       S->A: Abolishes inactivation by
FT                                phosphorylation; when associated with A-
FT                                232 and A-293.
FT                                {ECO:0000269|PubMed:7782287}.
FT   CONFLICT    278    278       G -> E (in Ref. 9; BAG35194).
FT                                {ECO:0000305}.
FT   CONFLICT    301    301       Y -> S (in Ref. 15; AAD23857).
FT                                {ECO:0000305}.
FT   CONFLICT    306    306       E -> D (in Ref. 15; AAD23857).
FT                                {ECO:0000305}.
FT   CONFLICT    349    349       A -> P (in Ref. 6; AAA60055).
FT                                {ECO:0000305}.
FT   CONFLICT    354    354       T -> A (in Ref. 6; AAA60055).
FT                                {ECO:0000305}.
FT   STRAND       32     37       {ECO:0000244|PDB:2OZL}.
FT   STRAND       42     45       {ECO:0000244|PDB:2OZL}.
FT   STRAND       52     57       {ECO:0000244|PDB:2OZL}.
FT   HELIX        58     83       {ECO:0000244|PDB:2OZL}.
FT   STRAND       85     87       {ECO:0000244|PDB:3EXF}.
FT   HELIX        98    106       {ECO:0000244|PDB:2OZL}.
FT   STRAND      112    115       {ECO:0000244|PDB:2OZL}.
FT   HELIX       121    126       {ECO:0000244|PDB:2OZL}.
FT   HELIX       131    138       {ECO:0000244|PDB:2OZL}.
FT   TURN        145    148       {ECO:0000244|PDB:2OZL}.
FT   HELIX       151    153       {ECO:0000244|PDB:3EXE}.
FT   TURN        167    169       {ECO:0000244|PDB:2OZL}.
FT   HELIX       170    184       {ECO:0000244|PDB:2OZL}.
FT   STRAND      190    195       {ECO:0000244|PDB:2OZL}.
FT   HELIX       198    200       {ECO:0000244|PDB:2OZL}.
FT   HELIX       202    213       {ECO:0000244|PDB:2OZL}.
FT   STRAND      218    224       {ECO:0000244|PDB:2OZL}.
FT   STRAND      226    228       {ECO:0000244|PDB:2OZL}.
FT   HELIX       233    236       {ECO:0000244|PDB:2OZL}.
FT   HELIX       242    244       {ECO:0000244|PDB:2OZL}.
FT   TURN        245    248       {ECO:0000244|PDB:2OZL}.
FT   STRAND      251    255       {ECO:0000244|PDB:2OZL}.
FT   HELIX       259    274       {ECO:0000244|PDB:2OZL}.
FT   TURN        275    277       {ECO:0000244|PDB:3EXG}.
FT   STRAND      280    285       {ECO:0000244|PDB:2OZL}.
FT   STRAND      300    302       {ECO:0000244|PDB:2OZL}.
FT   HELIX       304    314       {ECO:0000244|PDB:2OZL}.
FT   HELIX       316    326       {ECO:0000244|PDB:2OZL}.
FT   HELIX       332    355       {ECO:0000244|PDB:2OZL}.
FT   HELIX       361    363       {ECO:0000244|PDB:2OZL}.
FT   STRAND      367    371       {ECO:0000244|PDB:2OZL}.
FT   STRAND      375    378       {ECO:0000244|PDB:2OZL}.
FT   STRAND      385    388       {ECO:0000244|PDB:2OZL}.
SQ   SEQUENCE   390 AA;  43296 MW;  4D685BBE44A92D4B CRC64;
     MRKMLAAVSR VLSGASQKPA SRVLVASRNF ANDATFEIKK CDLHRLEEGP PVTTVLTRED
     GLKYYRMMQT VRRMELKADQ LYKQKIIRGF CHLCDGQEAC CVGLEAGINP TDHLITAYRA
     HGFTFTRGLS VREILAELTG RKGGCAKGKG GSMHMYAKNF YGGNGIVGAQ VPLGAGIALA
     CKYNGKDEVC LTLYGDGAAN QGQIFEAYNM AALWKLPCIF ICENNRYGMG TSVERAAAST
     DYYKRGDFIP GLRVDGMDIL CVREATRFAA AYCRSGKGPI LMELQTYRYH GHSMSDPGVS
     YRTREEIQEV RSKSDPIMLL KDRMVNSNLA SVEELKEIDV EVRKEIEDAA QFATADPEPP
     LEELGYHIYS SDPPFEVRGA NQWIKFKSVS
//
